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Abstract
This study evaluated the detection of tumors using in vivo imaging with a commercially available and systemically
administered protease-activatable fluorescent probe, ProSense. To this end, we analyzed the delivery and uptake
of ProSense as well as the target protease and its cellular source in a mouse xenograft tumor model. In vivo and
ex vivo multiwavelength imaging revealed that ProSense signals accumulated within tumors, with preferential dis-
tribution in the vascular leakage area that correlates with vasculature development at the tumor periphery. Immuno-
histochemically, cathepsin B, which is targeted by ProSense, was specifically localized in macrophages. The
codistribution of tenascin C immunoreactivity and gelatinase activity provided evidence of tissue-remodeling
at the tumor periphery. Furthermore, in situ zymography revealed extracellular ProSense cleavage in such areas.
Colocalization of cathepsin B expression and ProSense signals showing reduction by addition of cathepsin B
inhibitor was confirmed in cultured macrophage-derived RAW264.7 cells. These results suggest that increased
tissue-remodeling activity involving infiltration of macrophages is a mechanism that may be responsible for the
tumor accumulation of ProSense signals in our xenograft model. We further confirmed ProSense signals at the
tumor margin showing cathepsin B+ macrophage infiltration in a rat colon carcinogenesis model. Together, these
data demonstrate that systemically administered protease-activatable probes can effectively detect cancer invasive
fronts, where tissue-remodeling activity is high to facilitate neoplastic cell invasion.
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Introduction
Molecular imaging using exogenous tumor-specific fluorescent
probes is becoming an essential tool for the study of diseases, thera-
peutic effects, and clinical applicability [1–3]. Human clinical studies
for diagnostic and image-guided surgery are also emerging [4,5]. Tumor
imaging with fluorescent probes has the potential to promote a para-
digm shift in surgical inspection by enabling the localization of lesions
that are difficult or impossible to detect by visual observation or pal-
pation. This improved tumor detection can then improve patient out-
comes by identifying much smaller lesions and/or excising tumor tissue
more completely. However, the factors affecting tumor imaging per-
formance, such as target molecule activity, tumor growth environment,
vasculature, and stromal components, can vary on the basis of the
fluorescent probe design and type of cancer. Therefore, to assess their
clinical applicability, it is important to understand how the biologic
characteristics of these tumors affect the in vivo imaging of these
fluorescent probes.
Proteases have pivotal roles in altering local microenvironments dur-
ing embryonic development and growth as well as in both physiological
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and pathologic tissue-remodeling processes. Cysteine cathepsins, sim-
ply referred to as cathepsins in this study, consist of 11 family members
in humans (B, C, H, F, K, L, O, S, L2/V, W, and X/Z). Cathepsins
collectively have important roles in lysosomal protein degradation and
individually contribute to pathologic conditions [6]. Specifically,
cathepsin B is one of the most prominent proteases in the tumor pro-
teolytic network and is upregulated in many different tumor micro-
environments, from early neoplastic to advanced metastatic lesions
[7,8]. Cathepsin B is frequently translocated from lysosomes to the cell
surface and/or secreted into the extracellular matrix of tumor cells to
help their invasive growth by local activation of tissue proteolysis
[9,10]. The central role of cathepsin B in carcinogenesis suggests that
it is not only a promising target for chemotherapy and chemopreven-
tion but also for tumor detection.
Previous reports have shown that in vivo fluorescent imaging of
cathepsin B activity is capable of detecting tumors with high sensi-
tivity [11]. The cathepsin probe is an activatable graft copolymer
coupled with quenched fluorophores that are released after cathepsin
B cleavage, which allows for the detection of small or early lesions.
The probe is also designed for prolonged circulation by attaching
several polyethylene-glycol side chains to the polymer. A commercially
available probe, ProSense, is preferentially hydrolyzed by cathepsin B
but can also be activated through proteolysis by other cathepsins, such
as cathepsin L and cathepsin S. ProSense has been shown to detect a
variety of experimentally induced tumors of the colon, ovary, mammary
gland, pancreas, and esophagus [12–16]. However, the mechanisms
underlying the tumor specificity of ProSense signals are still unclear
because this probe is exposed to numerous complex in vivo processes.
Systemically administered ProSense is delivered to tumor tissue during
prolonged circulation, cleaved by target cathepsins in the local tumor
microenvironment, and is then retained within the tumor tissue.
Therefore, each of these processes needs to be investigated, as well as
the relationship between them within the same tumor, to clearly under-
stand the tumor specificity of ProSense.
In this study, we aimed to clarify how the biological characteristics of
tumors affect the in vivo imaging of systemically administered protease-
activatable fluorescent probes. For this purpose, we performed a time-
course analysis of delivery and uptake of ProSense in a mouse xenograft
model at both the macroscopic and microscopic levels using in vivo
and ex vivo multiwavelength imaging techniques. We then determined
the target molecules and cellular sources that generate the ProSense-
cleaving activity within the tumor. We further confirmed the specificity
of ProSense signals with protease expression in cultured cells. To inves-
tigate the influence of inflammation and immunity as well as carcino-
genesis on the tumor microenvironment, we analyzed ProSense signals
in an immunocompetent rat colon carcinogenesis model induced by
azoxymethane (AOM).
Materials and Methods
Cancer Cell Lines
Human colon tumor cell lines HT29 and HCT116 and a murine
macrophage-derived cell line RAW264.7 were purchased from DS
Pharma Biomedical (Osaka, Japan). HT29 or HCT116 cells were
cultured in McCoy’s 5A medium (Life Technologies, Carlsbad, CA)
supplemented with 10% FBS, 100 U/ml penicillin, and 0.1 mg/ml
streptomycin. RAW264.7 cells were cultured in Dulbecco’s modi-
fied Eagle’s (DME) medium (Life Technologies) supplemented with
10%FBS, 100U/ml penicillin, and 0.1mg/ml streptomycin. Cells were
routinely passaged at subconfluence. Only low-passage cells (passage <
10 times) were used.
Animal Model
Todevelop a xenograft tumormodel, a total of 12male BALB/c nu/nu
mice (4 weeks old) were purchased from Japan SLC Inc (Hamamatsu,
Japan). They received CA-1 (CLEA Japan Inc, Tokyo, Japan) as a basal
diet and tap water ad libitum period. At 5 to 6 weeks of age, the mice
were inoculated subcutaneously with 5 × 106 HT29 or HCT116 cells
in 0.1 ml of medium.
To develop an immunocompetent colon carcinogenesis model,
11 male F344 rats (4 weeks old) were purchased from Japan SLC
Inc. The rats received CE-2 (CLEA Japan Inc) as a basal diet and
water ad libitum throughout the experimental period. Starting at
6 weeks of age, rats were given subcutaneous injections of AOM
(Sigma-Aldrich, St Louis, MO; 15 mg/kg body weight) once a week
for 3 weeks as described previously [17].
All animal experiments were performed in accordance with the
guidelines for animal experimentation of the Facility of Agriculture,
Tokyo University of Agriculture and Technology.
In Vivo and Ex Vivo Imaging
To detect cathepsin activity, we used ProSense 750/750 EX
(PerkinElmer, Waltham, MA). To visualize the architecture of the
blood vessels, we used fluorescein-conjugated Lycopersicon esculentum
lectin (fluorescein–tomato lectin; Vector Laboratories Inc, Burlingame,
CA) or DyLight 594-conjugated Lycopersicon esculentum lectin
(DyLight 594-tomato lectin; Vector Laboratories Inc) [18]. We used
a blood pool imaging agent, AngioSense 680/680 EX (PerkinElmer),
to detect nonspecific probe delivery and uptake [19].
To image whole animals noninvasively, we used an epifluorescence
imaging system (OV100; Olympus, Tokyo, Japan). We used a multi-
wavelength laser scanning microscope (IV100; Olympus) to acquire
high-magnification and high-resolution images.
In the mouse xenograft tumor model, in vivo imaging was per-
formed 1 to 3 weeks after inoculation of tumor cells. To reduce auto-
fluorescence derived from the animals’ intestinal contents, mice
received an alfalfa-free CA-1 diet (CLEA Japan Inc) 2 to 3 days
before in vivo imaging [20]. A solution mixture of 2 nmol each of
ProSense 750 and AngioSense 680 in a total volume of 165 μl was
injected intravenously into tumor-bearing mice. To capture the
distribution kinetics of these reagents, fluorescent images were taken
10 minutes and 24 to 30 hours after injection. Fluorescein–tomato
lectin (200 μg/100 μl) was injected intravenously and allowed
to circulate for 5 minutes, followed by imaging. Mice were euthanized
immediately after in vivo imaging, and tumors were excised and cut
in half longitudinally. Ex vivo imaging of the tumor cut surface was
performed to analyze the distribution of reagents within the tumor
tissue. After ex vivo imaging, tissues were fixed in phosphate-buffered
10% formalin (pH 7.4) for at least 24 hours. The other half of
the tissue sample was snap frozen in liquid nitrogen. To measure
the probe fluorescent intensity, whole-animal and high-resolution
images were first obtained by the OV100 and IV100 microscopes,
respectively, and then analyzed using their respective software.
In the rat colon carcinogenesis model, a solution mixture of 10 nmol
of ProSense 750/750 EX and 5 nmol of AngioSense 680/680 EX in a
total volume of 450 μl was injected intravenously 23 to 27 hours before
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euthanasia at 28 to 37 weeks post-initiation. DyLight 594-tomato
lectin (250 μg/250 μl) was injected intravenously and allowed to cir-
culate for 20 minutes before euthanasia. Tumors were excised and pro-
cessed for histologic analysis or immunofluorescence. Ex vivo imaging
of the tumor cut surface was performed as described above.
Histology, Immunohistochemistry, and Immunofluorescence
To identify ProSense+-tissue component(s) within the tumor tissue,
unfixed cryosections from ProSense 750-injected tissue sample were
scanned with IV100, fixed with 4% paraformaldehyde, and then
immediately stained with hematoxylin and eosin (H&E) for micro-
scopic observation. AOM-induced rat colon tumors were diagnosed
according to previously published criteria [21].
Immunohistochemistry (IHC) was performed in paraffin-embedded
tissue sections by incubation with primary antibodies referred to in
TableW1. Immunodetectionwas carried out with anHRP-avidin-biotin
complex using a VECTASTAIN Elite ABC kit (Vector Laboratories
Inc), with DAB/H2O2 as the chromogen. Sections were counterstained
with hematoxylin.
Immunofluorescence was performed using methanol-fixed cryo-
sections for mouse tissues or paraffin-embedded tissue sections for
rat tissues and the antibodies referred to in Table W1. The sections
were incubated with primary antibodies and then with species-
appropriate Alexa Fluor-conjugated antibodies (1:200; Life Technolo-
gies) and counterstained with 4′,6-diamidino-2-phenylindole, dilactate
(DAPI; Life Technologies).
Microscopic observation was performed with a fluorescent virtual
microscopy system (VS120 Fluorescence; Olympus) or a fluorescent
microscope (BX53; Olympus). Fluorescent images were analyzed using
IV100 software.
Cultured Cell Experiments
For in vitro detection of ProSense signals and cathepsin B immuno-
expression, HT29, HCT116, or RAW264.7 cells (4 × 104) were seeded
into a noncoated chamber slide (81 mm2 per chamber; Iwaki, Tokyo,
Japan). After 2 days, the medium was replaced with Hank’s balanced
salt solution (HBSS) containing 5 nM ProSense 680 (PerkinElmer).
After incubation at 37°C for 3 hours, nuclear labeling was performed
with Hoechyst 33342 (Life Technologies). The unfixed cultured cells
were scanned with VS120 Fluorescence, fixed with methanol, and then
stained for cathepsin B by immunofluorescence. For coculture experi-
ment, HT29 or HCT116 cells (4 × 104) were seeded into a noncoated
chamber slide. After 1 day, RAW264.7 cells (0, 4, 10, or 20 × 104) were
added into the chamber and allowed to adhere and grow in culture
medium containing 10% FBS/DME’s medium for 1 day. ProSense
signals were detected as described above, followed by immunofluorescence
of cathepsin B with CD45. For protease inhibition assay, RAW264.7
cells were cultured in the presence of cell-permeable pan-cathepsin in-
hibitor (E64d; Sigma-Aldrich) or cell-permeable cathepsin B inhibitor
(CA074Me; EMD Millipore, Billerica, MA). RAW264.7 cells (4 ×
104) were seeded into a noncoated chamber slide. After 2 days, the
medium was replaced with HBSS containing vehicle (DMSO), E64d
(5, 25, or 50 nM), or CA074Me (5, 25, or 50 nM). After incubating at
37°C for 1 hour, 5 nM of ProSense in the presence or absence of
inhibitor was added, and the cells were incubated at 37°C for 3 hours.
ProSense signals were detected as described above. All experiments
were performed in duplicate.
In Situ Zymography
In situ zymography was performed on the fresh-frozen sections
according to the method described previously [22], with some mod-
ifications. Gelatinase activity or ProSense-cleaving activity was
detected in an unfixed cryosection using fluorescein-quenched gela-
tin (DQ gelatin; Life Technologies) or ProSense 680, respectively.
Cryosections were overlaid with a solution of 50 mg/ml DQ gelatin
or 13 nmol/ml ProSense 680, mixed with 1% (wt/vol) low–melting
temperature agarose in phosphate-buffered saline (PBS; pH 7.4) con-
taining propidium iodide (BD Biosciences, San Jose, CA) or DAPI to
counterstain nuclei. Fluorescent images were acquired using either
the IV100 or BX53 microscope.
Statistical Analysis
Fluorescent intensity data from the whole-animal images between the
two groups were compared using a Student’s t test when the variance was
proven to be homogeneous among the groups by the equal variance test.
When a significant difference in variance was observed, Aspin-Welch
t test was performed. P values <.05 were considered significant.
Results
ProSense Signals in Xenograft Tumor Model
Although histopathologic patterns of xenograft tumors were differ-
ent between HT29 and HCT116 in terms of the production of stro-
mal connective tissue (Figure W1), both xenograft tumors showed
tumor-specific ProSense signals with a significant increase in fluores-
cence relative to the skin (Figure 1, A and B). Compared with tumors,
the liver and kidney revealed strong signals, whereas the colon and
muscle resulted in weak signals (Figure W2). High-magnification
(×20) images showed that ProSense signals in the liver and kidney
were localized in Kupffer cells and renal tubular epithelial cells,
respectively (Figures W2 and W3).
The whole-tumor view at the cut surface showed that ProSense
signals were primarily in stromal tissue at the tumor periphery and
between the tumor parenchyma but rarely within the tumor paren-
chyma (Figure 1C ). At high magnification (×20), strong ProSense
signals were observed in the stromal area in both of the two xenograft
tumors (Figure 1D and data not shown).
In Vivo Delivery and Uptake of ProSense within
Tumor Xenografts
In vivo imaging revealed that AngioSense signals increased slowly
within tumor portions after injection of the probes, reflecting vascu-
lar leakage of AngioSense specific to tumors (Figure 2A). Similar to
AngioSense, ProSense also slowly increased within tumors, although
the kidney showed a rapid increase in ProSense signals within 10 min-
utes after injection, reflecting renal clearance of uncleaved ProSense
probes. Ear tissue rarely showed any increase in either AngioSense
or ProSense signals (Figure 2B ).
With ex vivo tumor imaging, we observed that ProSense signals
were localized within cell cytoplasm, whereas AngioSense signals
were broadly distributed in interstitial tissue (Figure 2C ). Whole-
tumor images at the cut surface showed tomato lectin signals in con-
junction with the vasculature at the tumor periphery, but the tumor
center showed reduced signals. This reflects the low density of the
vasculature in the center compared with the tumor periphery
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(Figure 2D). Similarly, AngioSense signals were also primarily observed
at the tumor periphery. Merged images of tomato lectin signals, Angio-
Sense signals, and ProSense signals demonstrated that ProSense signals
were distributed in areas showing high vascular density. At high mag-
nification (×20), ProSense+ cells were preferentially observed in areas
with increased vascular leakage at the tumor periphery, in contrast to
the weak signals observed in areas with low vascular leakage at the
tumor center (Figure 2E). Intensity profile analysis for tomato lectin
or AngioSense with ProSense corroborated the imaging results of these
signal distributions (Figure 2F).
Immunoreactivity for Cathepsins and Their Cellular Identity
in Tumor Xenografts
Immunolocalization of cathepsin B, cathepsin L, and cathepsin S
was similarly observed in the stroma at the tumor periphery (Figure 3,
A–C ). Cathepsin B localized strongly in the cytoplasm of stromal cells
and faintly in the cytoplasm of tumor cells. These stromal cathepsin B+
cells were prominently observed at the tumor periphery. Although
fewer stromal cells were distributed between tumor lobules than in the
tumor periphery, those distributed between tumor lobules also showed
strong cathepsin B immunoreactivity. With regard to cathepsin L, im-
munoreactive cells also showed weak cytoplasmic expression in the
stroma at the tumor periphery, rarely in the tumor parenchyma, and
no expression in tumor cells. Cathepsin S localized in the cytoplasm of
stromal cells at the tumor periphery and at the interlobular connective
tissue and also diffusely but weakly in the cytoplasm of tumor cells.
The distribution of ProSense signals was found to be more closely re-
lated to that of cathepsin B than that of other cathepsins (Figures 2D
and 3, A–C). ProSense signals were largely colocalized with cathepsin B
fluorescence in the stromal areas at the tumor periphery (Figure 3D).
Colocalization of ProSense signals and cathepsin B was also confirmed
in Kupffer cells in mouse livers (Figure W3).
In conjunction with cathepsin B immunoreactivity, CD68+ cells dis-
tributed mostly at the tumor periphery (Figure 4A). There was a good
correlation between CD68 with cathepsin B in a scattergram. However,
scattergrams of α–smooth muscle actin (SMA)+ or CD31+ cells with
cathepsin B showed a “two-tailed” split [23], reflecting a dissociation
of their distribution with cathepsin B (Figure 4, A–C ). Imaging of
double-stained cathepsin B and CD68 tissue under high magnification
(×20) also revealed identical cellular distribution of these immuno-
reactivities. Furthermore, immunofluorescence of cathepsin B with
other leukocyte markers, CD45, CD11b, Gr-1, or F4/80, in serial sec-
tions revealed that cathepsin B-expressing cells mostly coexpress all of
these markers similarly with CD68 (Figure W4). Again, CD31 and
α-SMA did not colocalize with cathepsin B, except for the colocaliza-
tion of α-SMA with cathepsin B in blood vessel walls (Figure 4, A–C).
Intensity profiling data showed similar distribution patterns between
cathepsin B and CD68 or CD31, corresponding to the profile of
ProSense signals and vascular probe signals within the tumor tissue
(Figure 2F and Figure 4, B and C). α-SMA immunoreactivity, how-
ever, did not show a similar intensity profile (Figure 2F and Figure 4,
A and C). Colocalization of ProSense signalswas observedwith immuno-
fluorescence of cathepsin B or CD68 in identical tissue section imaging
(Figure 4D).
In vitro studies using cultured cells revealed that RAW264.7, a
murine macrophage-derived cell line, showed high ProSense signals
and strong cathepsin B immunoreactivity, whereas HT29 or
HCT116 cells showed low ProSense signals and weak cathepsin B
Figure 1. In vivo imaging of ProSense in a mouse xenograft
tumor model using HCT116 and HT29 human colon tumor cell lines.
(A) Whole-body imaging of ProSense. Left: Bright field. Middle:
Autofluorescence before injection of ProSense. Right: ProSense at
1 day post-injection. Asterisks indicate the kidneys. Scale bar, 10mm.
(B) Tumor-to-skin ratio of average ProSense fluorescent intensity in
each tumor. Error bars represent means ± SD (n = 6). **P < .01
and *P < .05 (Aspin-Welch t test). (C) Ex vivo cut surface image of
the HT29 tumor. Left: ProSense. Right: H&E-stained view of the
tumor corresponding to the fluorescent image. Scale bars, 1 mm.
(D) High-magnification (×20) view of ProSense image at the tumor
periphery. Left: ProSense (red) with tissue autofluorescence rep-
resents connective tissue (green). Right: H&E-stained view of the
tumor corresponding to the fluorescent image. Scale bars, 100 μm.
TP, tumor parenchyma; S, stroma. (A, C, and D) Six animals exam-
ined showed similar results. All images are from the same animal.
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immunoreactivity (Figure 5A and data not shown). Coculture ex-
periments of HT29 or HCT116 cells with RAW264.7 cells showed
that ProSense signals were increased with the increase in the co-
culture ratio of CD45+ cathepsin B+ RAW264.7 cells (Figure 5, B
and C , and data not shown). ProSense signal of RAW264.7 cells
was inhibited by pan-cathepsin inhibitor, E64d, or cathepsin B
inhibitor CA074Me in a dose-dependent manner (Figure 5, D
and E ).
Figure 2. In vivo imaging of ProSense with vascular imaging probes, tomato lectin, and AngioSense in a mouse xenograft tumor model
using HCT116 and HT29 human colon tumor cell lines. (A) Whole-body time-lapse imaging of AngioSense (upper panels) and ProSense
(lower panels). Left: Autofluorescence before probe injection. Middle: AngioSense or ProSense within 10 minutes after injection. Right:
AngioSense or ProSense at 1 day post-injection. Asterisks indicate ProSense signals in the kidney. The arrows indicate large blood
vessels around the tumor. The arrowheads indicate autofluorescence derived from animals’ intestinal contents. Scale bar, 10 mm.
(B) Noninvasive time-lapse imaging of AngioSense (blue) and ProSense (red) in the HT29 tumor (upper panels) and ear (lower panels).
Left: Merged images of AngioSense and ProSense within 10 minutes after injection. Note the lack of ProSense signals and the auto-
fluorescent signals of the hair follicles (green). Right: Merged images of AngioSense, ProSense, and tomato lectin 1 day after injection
of AngioSense and ProSense and 5 minutes after injection of tomato lectin (green). Arrowheads indicate identical portions of vascula-
ture. Scale bar, 500 μm. (C) Ex vivo imaging of the HT29 tumor surface with tomato lectin (green), AngioSense (blue), and ProSense (red).
Upper panel: Low-magnification (×4) view. Lower panel: High-magnification (×20) view of boxed area as shown in the upper panel.
Scale bar for the low-magnification view, 500 μm; for the high-magnification view, 100 μm. (D) The whole-tumor view of the cut surface
imaging of the HT29 tumor. Left: Tomato lectin image. Middle left: AngioSense. Middle right: ProSense. Right: Merged image. Scale
bar, 1 mm. (E) High-magnification (×20) view of the cut surface imaging of the HT29 tumor at the tumor periphery (upper panels) and
tumor center (lower panels) as shown in the boxed areas of D. Scale bar, 100 μm. (F) Histogram of the fluorescent intensity with tomato
lectin (green), AngioSense (blue), and ProSense (red). The fluorescent intensity profile was measured on the merged image (arrow) and
plotted. (A–F) Five animals examined showed similar results. All images are from the same animal.
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Tumor Proliferation and Tissue-Remodeling Activity in a
Xenograft Tumor Model
IHC for proliferating cell nuclear antigen (PCNA) revealed higher
proliferative activity of tumor cells at the tumor periphery than at the
center (Figure 6A). Collagen IV immunoreactivity was rarely observed
at the tumor margin, in contrast to the scattered distribution in stro-
mal cells within tumor parenchyma. Unlike collagen IV, tenascin C
immunoreactivity was observed at the tumor margin. Gelatinase
activity also showed a similar pattern of immunoreactivity as tenascin C
by in situ zymography of DQ gelatin (Figure 6B). In situ zymography of
ProSense revealed that ProSense cleavage was observed at the collage-
nous tissue components at the tumor periphery (Figure 6C ).
ProSense Signals in a Rat Colon Carcinogenesis Model
Ex vivo imaging detected ProSense signals in rat colon tumors in-
duced by AOM (Figure 7A). The whole-tumor view at the cut sur-
face showed ProSense signals distributed at the tumor margin
showing high vascular density and increased vascular leakage
(Figure 7B). These ProSense signals were localized within the cell cy-
toplasm (data not shown). Double staining of cathepsin B and CD68
showed cathepsin B+ macrophages had infiltrated the tumor margin,
corresponding to ProSense signals within the tumor (Figure 7, B and
C ). α-SMA and CD31, however, did not show colocalization with
cathepsin B, except for the colocalization of α-SMA with cathepsin B
in blood vessel walls. In some tumors, tumor cells appeared to
express cathepsin B, in contrast to the lack of cathepsin B expression
in the adjacent normal colon mucosa.
Discussion
In this study, we observed a time-dependent accumulation of Angio-
Sense in xenograft tumors by selective leakage from the microvascu-
lature identified by tomato lectin. This is suggestive of an enhanced
permeability and retention (EPR) effect of macromolecules [24]. We
also observed a slow accumulation of ProSense signals in the areas
showing EPR effects within tumors. These data suggest that Pro-
Sense probes are delivered to tumors in this manner. Alternatively,
it is possible that ProSense probes could be effectively delivered to,
and accumulate in, areas with increased vascular leakage similar to
AngioSense probes. Furthermore, we observed this EPR effect in
the rat colon carcinogenesis model, which partially recapitulates clin-
ical carcinogenesis. Our results suggest that EPR effect-based imag-
ing agents like ProSense can be applicable in clinical settings for
tumor detection.
We also observed that the cytoplasmic localization patterns of Pro-
Sense signals showed a similar distribution with cathepsin B+ macro-
phages in tumor xenografts. The accumulation of ProSense signals
has also been reported in conjunction with intestinal polyp accumu-
lating macrophages in a genetically engineered mouse model [25].
ProSense+ macrophages were also found in mouse xenograft gliomas
[26]. In the present study, we also found that cultured cells of
RAW264.7, a macrophage-derived cell line, revealed cathepsin B
expression and high ProSense signals. These results suggest that
ProSense+ cells in our tumor xenografts were cathepsin B+ macro-
phages. We further found extracellular ProSense-cleaving activity in
areas with accumulating cathepsin B+ macrophages. Considering the
Figure 3. Immunoreactivity for cathepsins targeted by ProSense in the HT29 tumor. (A–C) Cathepsins B, L, and S, respectively, in
the tumor shown in Figure 2. Left: Whole-tumor view. Right: High-magnification (×20) view at the tumor periphery. Scale bar for
the whole-tumor view, 1 mm; for the high-magnification view, 20 μm. (D) Cathepsin B immunoreactivity and ProSense signals at the
tumor periphery in the tumor shown in Figure 1. Left: H&E. Middle: ProSense (red) at the area of the H&E-stained view with tissue
autofluorescence representing connective tissue (green). Right: Cathepsin B (green) with nuclear DAPI staining (blue). The dotted
lines indicate identical portions of the tumor stroma. Scale bar, 100 μm. (A–D) Tumors from at least five animals examined showed
similar results.
Translational Oncology Vol. 6, No. 6, 2013 In Vivo Imaging of Protease-Activatable Probe Onda et al. 633
cytoplasmic localization of ProSense signals, we suggest that Pro-
Sense probes are incorporated into macrophages after cleavage by
cathepsin B in the extracellular space. ProSense signals were also
observed in the liver Kupffer cells and cultured RAW264.7 cells, sug-
gesting that phagocytosed uncleaved ProSense could also be cleaved
within lysosomes.
It has been reported that tumor cells could contribute to the accu-
mulation of ProSense probes [15]. However, the xenograft tumor
models used in the present study showed only low ProSense signals,
consistent with the faint expression of cathepsin B we observed in
colon tumor cells. In the AOM-induced colon tumors, although we
could not detect ProSense signals in tumor cells, cathepsin B was
Figure 4. Colocalization analysis of immunofluorescence images for cathepsin B and markers for macrophages, myofibroblasts,
and endothelial cells in the HT29 tumor. (A–C) Immunoreactivities for cathepsin B (green) with CD68, α-SMA, or CD31 (red) in the
tumor shown in Figure 3D. Left: Whole-tumor view with nuclear DAPI staining (blue). Middle left: High-magnification (×20) view
of the immunofluorescent signals. The dotted lines indicate identical portions of the tumor stroma. Middle right: Scattergram data
from the whole-tumor images. Right: Histogram of the fluorescent intensity from the whole-tumor images (arrow). Scale bar for the
whole-tumor view, 1 mm; for the high-magnification view, 50 μm. (D) ProSense signals and immunoreactivities of cathepsin B and CD68
in an identical section. Left: ProSense signals. Middle left: Cathepsin B immunoreactivity. Middle right: CD68 immunoreactivity.
Right: Merged image. Scale bar, 50 μm. T, tumor; M, muscle; BV, blood vessel. (A–D) Tumors from at least three animals examined
showed similar results.
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expressed in some tumor cells. Together, these data suggest that
macrophages are the major source of ProSense signals in tumor tissues,
consistent with previous reports [27]. Therefore, ProSense signal inten-
sity is likely determined by the degree of macrophage infiltration.When
using these probes to detect tumors, it may be important to address not
only the level of cathepsin protease activity but also the endocytic
activity of the cells [28].
ProSense signals and cathepsin B+ macrophages in the tumor
xenografts were mainly distributed at the tumor periphery, where
we observed a higher density of vasculature and PCNA+ tumor cells
than in the center. Although we also observed the localization of
tenascin C and gelatinase activity at the tumor margin, collagen IV
did not accumulate in the same way as reported by others [29].
Tenascin C is an extracellular matrix glycoprotein that has a role
Figure 6. Proliferation and tissue-remodeling activity in the HT29
tumor. (A–C) Immunoreactivity of PCNA and extracellular matrix
proteins and in situ zymography in the tumor shown in Figure 3D.
(A) PCNA. Left: Whole-tumor view. Middle: High-magnification
(×20) view at the tumor periphery. Right: High-magnification (×20)
view at the tumor center. Scale bar for the whole-tumor view, 1 mm;
for the high-magnification view, 50 μm. (B) Immunoreactivity for
collagen IV and tenascin C and in situ zymography of DQ gelatin
at the tumor periphery with nuclear DAPI staining (blue). Left:
Cathepsin B (green) and collagen IV (red). Middle: Tenascin C
(red). Middle right: DQ gelatin-cleaving activity (green). Scale bar,
50 μm. (C) In situ zymography of ProSense. Left: ProSense-cleaving
activity (red) with nuclear propidium iodide staining (blue). Middle:
High-magnification (×20) view of ProSense-cleaving activity. Right:
High magnification (×20) of the H&E-stained view of the tumor
corresponding to the fluorescent image. Scale bar, 50 μm. The
dotted lines indicate identical portions of the tumor stroma. The
arrowheads indicate the tumor margin at the tumor periphery.
T, tumor; M, muscle. (A–D) Tumors from at least three animals
examined showed similar results.
Figure 5. ProSense signals in cultured HT29 human colon tumor
cells or RAW264.7 murine macrophage-derived cells. (A) ProSense
signals (red; upper panels) and cathepsin B immunoreactivity
(green; lower panels) with nuclear Hoechst staining (blue) in the
single-cell culture. Left: RAW264.7 cell image. Middle: HT29 cell
image with the same imaging parameters as RAW264.7 cell image.
Right: HT29 cell image with enhanced fluorescent intensities.
Scale bar, 10 μm. (B) Localization of ProSense signals and immuno-
reactivities of cathepsin B and CD45 in the coculture of HT29 and
RAW264.7 cells. Left: ProSense signals (red) with nuclear Hoechst
staining (blue). Right: Immunoreactivities of cathepsin B (green) and
CD45 (red) with nuclear Hoechst staining (blue). To avoid detecting
cocultured RAW264.7 cells as tumor cells, cells were stained with
anti-CD45 antibody by immunofluorescence. Scale bar, 10 μm. (C)
ProSense signals (red) in the coculture of HT29 and RAW264.7 cells
with different cell number ratio for cocultivation.Nucleuswascounter-
stained with Hoechst (blue). Left: Single-cell culture of HT29 cells.
Middle left: Coculture with 1:1 of HT29 cell–to–RAW264.7 cell ratio.
Middle right: Coculture with 1:2.5 of HT29 cell–to–RAW264.7 cell
ratio. Right: Coculture with 1:5 of HT29 cell–to–RAW264.7 cell ratio.
Scale bar, 200 μm. (D) ProSense signals of RAW264.7 cells in the
presence of pan-cathepsin inhibitor E64d. Left: Vehicle. Middle left:
5 nM. Middle right: 25 nM. Right: 50 nM. Scale bar, 10 μm. (E) Pro-
Sense signals of RAW264.7 cells in the presence of cathepsin B
inhibitor CA074Me. Left: Vehicle. Middle left: 5 nM. Middle right:
25 nM. Right: 50 nM. Scale bar, 10 μm.
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in tissue-remodeling [30]. In the present study, we further found
increased extracellular ProSense cleavage at the tumor periphery.
Although tumor xenografts did not show apparent invasive growth into
the surrounding tissues, these results suggest that tissue-remodeling
occurred at the tumor periphery in response to tumor proliferation.
We also found that cathepsin B+ macrophages were mainly distributed
around blood vessels at the tumor periphery. Macrophages that aggre-
gate around the tumor vasculature function in tissue-remodeling
[31,32]. Therefore, our results suggest that, in addition to the EPR
effect, the increase in tissue-remodeling involving cathepsin B+ macro-
phage infiltration is a potential mechanism for the accumulation of
ProSense signals within tumors.
We also evaluated how inflammation in the tumor microenvi-
ronment may affect ProSense accumulation within tumors using an
immunocompetent AOM-induced rat colon carcinogenesis model.
This immunocompetent model renders a natural tumor-host inter-
action. Notably, we could detect ProSense signals in conjunction with
increased vascular leakage at the tumor stroma, especially at the tumor
margin showing macrophage infiltration. Recent reports using immuno-
competent animal models have also detected tumors by enhancing Pro-
Sense signals at the tumor margin [14,33]. In human colorectal cancers,
invasive fronts express cathepsin B, showing high activity to facilitate
tissue-remodeling [34,35]. Although macrophage infiltration is posi-
tively correlated with a favorable outcome in some human colorectal
cancers, macrophages could be protumorigenic or antitumorigenic
depending on the degree of cellular contact with neoplastic cells [36–38].
These data suggest that ProSense can effectively detect cancer invasive
fronts where tissue-remodeling activity is high to facilitate neoplastic
cell invasion.
In conclusion, the higher ProSense delivery and uptake at the tumor
periphery are likely the result of the infiltration of cathepsin B+ macro-
phages in the stroma and the high-density vasculature. We also dem-
onstrated that ProSense signal activation occurs in the extracellular
space, and then the activated molecules accumulate in the macro-
phages. This suggests that ProSense is a clinically valuable tool for
the detection of malignant tumors that require tissue-remodeling.
Therefore, the clinical introduction of intraoperative protease imaging
may have the potential to improve the accuracy of tumor resections.
Figure 7. ProSense imaging in AOM-induced rat colon carcinogenesis model. (A) Ex vivo imaging of ProSense in a colon tumor. Left:
Bright field. Middle: AngioSense. Right: ProSense. Scale bar, 2 mm. (B) Cut surface imaging of the colon tumor. Left: Tomato lectin.
Middle: AngioSense. Right: ProSense. Scale bar, 1 mm. (C) Immunoreactivities for cathepsin B (green) with CD68, α-SMA, or CD31 (red)
and nuclear DAPI staining (blue) at the whole-tumor view (upper panels) or the high-magnification (×20) view (lower panels). Left: H&E-
stained view of the tumor corresponding to the fluorescent image as shown in B. Middle left: Cathepsin B and CD68. Middle right:
Cathepsin B and α-SMA. Right: Cathepsin B and CD31. Scale bar for the whole-tumor view, 500 μm; for the high-magnification view, 50 μm.
The asterisk indicates a necrotic area. (A–C) Tumors from at least seven animals examined showed similar results. All images are from
the same tumor.
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Table W1. Antibodies Used in the Present Study.
Antigen Host Species Clonality Application Dilution Antigen Retrieval* Manufacturer (City, State, Country)
Cathepsin B Goat Polyclonal IHC/IF(p)/IF(f )/ICF 1:1000/1:200/1:50/1:50 Autoclaving Santa Cruz Biotechnology, Inc (Dallas, TX)
Cathepsin L Rat Polyclonal IHC 1:100 Autoclaving R&D Systems (Minneapolis, MN)
Cathepsin S Goat Polyclonal IHC 1:25 Autoclaving Abcam (Cambridge, United Kingdom)
CD31 Rat Monoclonal IF(f ) 1:10 - BD Biosciences (San Jose, CA)
CD31 Rabbit Polyclonal IF(p) 1:50 Autoclaving Abcam
CD68 Rat Monoclonal IF(f ) 1:50 - AbD Serotec (Oxford, United Kingdom)
CD68 Mouse Monoclonal IF(p) 1:100 Autoclaving BMA Biomedicals (Augst, Switzerland)
CD45 Rat Monoclonal IF(f )/ICF 1:10/1:10 - BD Biosciences
CD11b Rat Monoclonal IF(f ) 1:10 - BD Biosciences
Gr-1 Rat Monoclonal IF(f ) 1:200 - AbD Serotec
F4/80 Rat Monoclonal IF(f ) 1:500 - BMA Biomedicals
α-SMA Rabbit Polyclonal IF(p)/IF(f ) 1:100/1:100 Autoclaving Abcam
PCNA Rabbit Polyclonal IHC 1:1000 Autoclaving Abcam
Collagen IV Rabbit Polyclonal IF(f ) 1:100 - Abcam
Tenascin C Rat Monoclonal IF(f ) 1:100 - Abcam
IHC, indicates immunohistochemistry; ICF, immunocytofluorescence; IF(p), immunofluorescence (paraffin sections); IF(f), immunofluorescence (frozen sections); TRS, target retrieval solution.
*Antigen retrieval was applied to paraffin-embedded tissue sections. Retrieval conditions were autoclaving at 121°C for 10 minutes, and the solution used was TRS at pH 6.0 (Dako, Glostrup, Denmark).
Figure W1. Histology for HT29 and HCT116 xenograft tumors. (A) Histology of HT29 tumor. Left: Whole-tumor view. Right: High-
magnification (×20) view. A well-demarcated tumor is formed in the subcutis with a scanty fibrous capsule. Tumor cell proliferation
with moderately produced connective tissue accompanied with formation of some tubular/glandular structures. (B) Histology of HCT116
tumor. Left: Whole-tumor view. Right: High-magnification (×20) view. A well-demarcated tumor is formed in the subcutis with a scanty
fibrous capsule. Sheet-like proliferation shows solid growth of tumor cells accompanied with scanty stromal connective tissue. Scale
bar for whole-tumor view, 1 mm; for high-magnification view, 20 μm. (A and B) Tumors from 12 animals examined showed similar
morphology. All images are from the same tumor.
Figure W2. Ex vivo imaging of ProSense and immunoreactivity for cathepsin B of organs/tissues in a mouse xenograft tumor model
using HCT116 and HT29 human colon tumor cell lines. (A) Macroscopic ex vivo ProSense imaging of organs/tissues. Left: Bright field.
Right: ProSense. Scale bar, 10 mm. (B) Tumor-to-organ/tissue ratio of average ProSense fluorescent intensity. Error bars represent
means ± SD (n = 3). (C–H) High-magnification (×20) view of ex vivo imaging of ProSense signals and IHC of cathepsin B in the lung
(C), liver (D), kidney (E), spleen (F), colon (G), and muscle (H). Left: ProSense signals (red) with tomato lectin (green). Imaging parameters
were optimized according to their fluorescent intensities. The kidney image was acquired from the cut surface. Scale bar, 100 μm. Right:
Cathepsin B immunoreactivity. Scale bar, 20 μm. (A–H) Three animals examined showed similar results. All images are from the
same animal.
Figure W3. ProSense signals in the liver tissue. (A) High-magnification (×40) view stained with H&E for comparison of view. Left: Pro-
Sense signals (red) with tomato lectin (green) in the liver. Scale bar, 50 μm. Right: H&E-stained view of the identical section. Arrows
indicate colocalization of ProSense signals with Kupffer cells. Scale bar, 20 μm. (B) Another high-magnification (×40) view stained with
cathepsin B for comparison of view. Left: ProSense signals (red) with tomato lectin (green) in the liver. Right: Cathepsin B immunore-
activity (red) with tomato lectin (green) of the identical section. Arrows indicate colocalization of ProSense signals with cathepsin B+
cells. Scale bar, 50 μm.
Figure W4. ProSense signals and immunoreactivities of cathepsin B with leukocyte markers in the serial sections at the tumor periphery
of the HT29 tumor. (A) Frozen tissue section image of ProSense signals (red) with tissue autofluorescence (green). Scale bar, 100 μm.
(B–F) Immunofluorescence of cathepsin B with leukocyte markers CD45 (B), CD11b (C), Gr-1 (D), CD68 (E), and F4/80 (F). High-magnification
(×20) view of boxed area in A. Left: Cathepsin B immunoreactivity (green) with nuclear DAPI staining (blue). Middle: Leukocyte marker
immunoreactivity (red) with nuclear DAPI staining (blue). Right: Merged image. CD45 was used as a pan-leukocyte marker. CD11b and
Gr-1 were used as a marker of myeloid-derived cells including granulocytes and macrophages. CD68 and F4/80 were used as a marker
of mature macrophages. Scale bar, 20 μm.
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